Sign up to The Irish Times Archive (1859 - 2008)My Account »

A NEW DRUG has slowed cognitive decline by up to 81 per cent in Alzheimer patients during early pharmaceutical trials, it has been announced.

The drug, Rember, claims to act on disruptive protein tangles that build up in brain cells as the condition progresses, and the outcome of early trials were presented last week at the International Conference on Alzheimer's disease in Chicago.